James Dentzer has served on the Board since September 2018, when he was appointed as a Director and as President and Chief Executive Officer. Mr. Dentzer, who joined Curis in 2016, was promoted in 2018 to Chief Operating Officer to manage all functions outside of research and development, including business development, manufacturing, quality, human resources, finance, legal, IT, and investor and public relations. He is also leading the pre-commercial strategic planning for fimepinostat, which received Fast Track designation from the FDA for the treatment of patients with Relapsed/Refractory DLBCL. Before joining Curis, Mr. Dentzer was Chief Financial Officer of Dicerna Pharmaceuticals, where he led the IPO and successful follow-on financings. Earlier in his career, he held several leadership positions with Valeritas, Amicus Therapeutics and Biogen. Mr. Dentzer earned a B.A. in Philosophy from Boston College and an M.B.A. from the University of Chicago’s Booth School of Business.